Samrat Pharmachem Limited reported an increase in topline revenue for FY26, though profitability metrics deteriorated significantly compared to the previous year. The pharmaceutical chemicals manufacturer recorded revenue of ₹289.72 crore, up from ₹285.86 crore in FY25. Despite the marginal top-line growth, EBITDA swung to a loss of ₹3.94 crore against a profit of ₹11.87 crore in the prior fiscal year.

The company disclosed these figures during its 34th Annual General Meeting held on September 23, 2026, via video conferencing. The meeting was chaired by Rajesh Mehta, Executive Director, who highlighted that the company incurred capital expenditure of approximately ₹6.29 crore during the financial year. Management stated that this investment is intended to boost production and sales capacity, aiming to cater to local manufacturers and meet export demands.

Financial Performance Overview

The shift in profitability amidst flat-to-slightly-up revenue growth suggests margin pressure or increased operational costs during FY26. The company did not disclose specific reasons for the EBITDA decline in the AGM summary, but noted plans to add new products to its existing range to drive future growth.

What the Numbers Show

A divergence is visible between the modest revenue expansion of roughly 1.4% and the sharp contraction in operating profitability. While revenue grew by ₹3.86 crore, EBITDA declined by ₹15.81 crore year-on-year. This indicates that costs rose disproportionately faster than sales, or that the new product additions and capex investments are currently weighing on margins before contributing to revenue conversion.

AGM Proceedings and Resolutions

The meeting was attended by 39 members through video conferencing. Key resolutions passed included:

• Adoption of audited standalone financial statements for FY26.
• Re-appointment of Megh Mehta as Executive Director.
• Appointment of statutory auditor and ratification of cost auditor remuneration.

The Statutory Auditor’s report for FY26 was unqualified. However, the Secretarial Auditor’s report was qualified, with observations read out by Practising Company Secretary Aqueel Mulla during the meeting. One shareholder raised questions regarding future prospects, which were addressed by the Chairman.

Samrat Pharmachem has scheduled its 34th Annual General Meeting (AGM) for Wednesday, September 23, 2026. The meeting will be conducted through Video Conferencing or Other Audio Visual Means at 1:00 pm.

The company announced the closure of its Register of Members and Share Transfer books from Sunday, September 20, 2026, to Tuesday, September 22, 2026. This period coincides with the remote e-voting window. Voting rights are determined by equity holdings as on Wednesday, September 16, 2026.

Voting Schedule

Shareholders can cast their votes electronically during the specified dates via MUFG Intime India Private Limited. The timeline is as follows:

Members who have cast their vote by remote e-voting prior to the AGM may also attend or participate in the AGM through VC/OAVM but shall not be entitled to cast their vote again. Those present in the AGM who had not cast votes remotely are eligible to vote during the meeting.

For technical issues regarding Insta Vote e-voting, members may refer to the FAQs available at the MUFG Intime website or contact the investor relations helpdesk at +918108116767.

Document Availability

The Annual Report for the financial year 2025-26, containing the notice for the meeting, is available on the company’s website. Nishant Kankaria, Company Secretary and Compliance Officer, signed the communication to the BSE Limited on August 27, 2026.

Members holding physical securities must update their KYC as per SEBI guidelines to receive dividends.